Classes of sigma 2 (σ 2) receptor ligands: Structure affinity relationship (SAfiR) studies and antiproliferative activity

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 938-949

  Abate, Carmen ^a   Perrone, Roberto ^a   Berardi, Francesco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Sigma 2 receptor ligands; Sigma 2 receptors; Structure affinity relationships

Indexed keywords

3 ETHYL 2,3 DIHYDRO 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE; 8 (3,4 DICHLOROBENZYLIDENE) 5 (3 HYDROXYPHENYL) 2 METHYLMORPHAN 7 ONE; 8 BENZYLIDENE 5 (3 HYDROXYPHENYL) 2 METHYLMORPHAN 7 ONE; BENZAMIDE DERIVATIVE; GRANATANE DERIVATIVE; IBOGAINE; INDOLE DERIVATIVE; ISO 1; LIGAND; MORHAN DERIVATIVE; PB 28; PIPERAZINE DERIVATIVE; RHM 1; SIGMA 2 OPIATE RECEPTOR; SIRAMESINE; SW 119; SW 43; UNCLASSIFIED DRUG; WC 26; WC 59; SIGMA OPIATE RECEPTOR; SIGMA-2 RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DRUG DESIGN; DRUG PURIFICATION; HUMAN; LIPOPHILICITY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; STRUCTURE AFFINITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; REVIEW;

ANIMALS; CELL PROLIFERATION; HUMANS; LIGANDS; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857133139     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436485     Document Type: Article

References (60)

1. Martin WR, Eades CE, Thompson JA, Huppler RE. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharmacol Exp Ther 1976; 197: 517-32.
2. Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85-6.
3. van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 2010; 16: 3519-37.
4. Wheeler KT, Wang LM, Wallen CA, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000; 82: 1223-32.
5. Al-Nabulsi I, Mach RH, Wang LM, et al. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 1999; 81: 925-33.
6. Hornick JR, Xu J, Vangveravong S, et al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol. Cancer. 2010, 9, 298.
7. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62: 313-22.
8. Kashiwagi H, McDunn JE, Simon PO, et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 2007; 6:48, available from http://www.molecular-cancer.com/content/6/1/48.
9. Kashiwagi H, McDunn JE, Simon PO, et al. Sigma-2 receptor ligands potentiate chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med 2009; 7:24 available from http://www.translational-medicine.com/content/7/1/24.
10. Colabufo NA, Berardi F, Contino M, et al. Antiproliferative and cytotoxic effects of some σ2 agonists and σ1 antagonists in tumour cell lines. Arch Pharmacol 2004; 370: 106-13.
11. Berardi F, Abate C, Ferorelli S, Colabufo NA, Perrone R. 1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (σ1) and sigma-2 (σ2) receptor ligands: a review. Cent. Nerv Syst Agents Med Chem 2009; 9: 205-19.
12. Perregaard J, Moltzen EK, Meier E, Sanchez C. σ Ligands with subnanomolar affinity and preference for the σ2 binding site. 1. 3-(w-Aminoalkyl)-1H-indoles. J Med Chem 1995; 38: 1998-2008.
13. Mach RH, Wheeler KT. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo. Cent Nerv Syst Agents Med Chem 2009; 9: 230-45.
14. Tu Z, Xu J, Jones LA, et al. Fluorine-18 labeled benzamide analogs for imaging the sigma-2 receptor status of solid tumors with positron emission tomography. J Med Chem 2007; 50: 3194-204.
15. Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB-184: ligands with high σ2 receptor affinity and subtype selectivity. Eur J Pharmacol 1995; 278: 257-60.
16. de Costa BR, He XS, Dominguez C, Cutts J, Williams W, Bowen WD. A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-Nmethyl-2-(1-pyrrolidinyl)ethylamine-related polyamines at σ1 and σ2 receptor subtypes. J Med Chem 1994; 37:314-21.
17. Mewshaw RE, Sherrill RG, Mathew RM, Kaiser C, Bailey MA, Karbon EW. Synthesis and in vitro evaluation of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles: high-affinity ligands for the N,N'-di-o-tolylguanidine-labeled σ binding site. J Med Chem 1993; 36:343-52.
18. Bertha CM, Mattson MV, Flippen-Anderson JL, et al. A marked change of receptor affinity of the 2-methyl-5-(3-hydroxyphenyl) morphans upon attachment of an (E)-8-benzylidene moiety: synthesis and evaluation of a new class of σ receptor ligands. J Med Chem 1994; 37: 3163-70.
19. Gebreselassie D, Bowen WD. Sigma-2 are specifically localized to lipid refts in rat liver membranes. Eur J Pharmacol 2004; 493: 19-28
20. Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther 2000; 292: 900-11.
21. Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE. Ibogaine and its congeners are σ2 receptor-selective ligands with moderate affinity. Eur J Pharmacol 1995; 279: R1-R3.
22. Moltzen EK, Perregaard J, Meier E. s Ligands with subnanomolar affinity and preference for the σ2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J Med Chem. 1995; 38: 2009-17.
23. Maier CA, Wunsch B. Novel spiropiperidines as higly potent and subtype selective σ-receptor ligands. part 1. J Med Chem 2002; 45: 438-48.
24. Heading C. Siramesine H Lundbeck. Curr Opin Investig Drugs 2001; 2: 266-70.
25. Ostenfeld MS, Fehrenbacher N, Hover-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005; 65: 8975-83.
26. Groth-Pedersen L, Ostenfeld MS, Høyer-Hansen M, Nylandsted J, Jäättelä M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 2007; 67: 2217-25.
27. Ostenfeld MS, Høyer-Hansen M, Bastholm L, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 2008; 4: 487-99.
28. Jonhede S, Petersen A, Zetterberg M, Karlsson J-O. Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extralysosomal proteolytic systems in lens epithelial cells. Molecular Vision 2010; 16: 819-27.
29. Parry MJ, Alakoskela JM, Khandelia H, et al. High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid. J Am Chem Soc 2008; 130: 12953-60.
30. Mamolo MG, Zampieri D, Zanette C, et al. Substituted benzylaminoalkylindoles with preference for the σ2 binding site. Eur J Med Chem 2008; 43: 2073-81.
31. Mach RH, Yang B, Wu L, Kuhner RJ, Whirrett BR, West T. Synthesis and sigma receptor binding affinities of 8-azabicyclo [3.2.1]octan-3-yl and 9-azabicyclo[3.3.1]nonao-3-yl phenylcarbamates. Med Chem Res 2001; 10: 339-55.
32. Mach RH, Vangveravong S, Huang Y, Yang B, Blair JB, Wu L. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3-yl phenylcarbamate analogs as sigma-2 receptor ligands. Med Chem Res 2003; 11: 380-398.
33. Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of Nsubstituted 9-azabicyclo[3.3.1]nonan-3-yl phenylcarbamate analogs as s2 receptor ligands. Bioorg Med Chem 2006; 14: 6988-897.
34. Chu W, Xu J, Dong Z, et al. New N-substituted 9-azabicyclo [3.3.1]nonan-3a-yl phenylcarbamate analogs as σ2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorg Med Chem 2009; 17: 1222-31.
35. Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and _2 receptor ligands. Bioorg Med Chem 2004; 14: 195-202.
36. Xu J, Tu Z, Jones LA, Wheeler KT, Mach RH. [3H]N-[4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. Eur J Pharmacol 2005; 525: 8-17.
37. Phase I Clinical Trial. ClinicalTrials.gov Identifier: NCT00968656. Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1 (PET/CT).
38. Xu R, Lever JR, Lever SZ. Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for σ receptors. Bioorg Med Chem Lett 2007; 17: 2594-97.
39. Fan KF, Lever JR, Lever SZ. Effect of structural modification on amine portion of substituted aminobutyl-benzamides as ligands for bindng σ1 and σ2 receptors. Bioorg Med Chem 2011; 19: 1852-59.
40. Abate C, Ferorelli S, Contino M, et al. Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers. Eur J Med Chem 2011; 46: 4733-41.
41. Berardi F, Ferorelli S, Abate C, et al. 4-(Tetralin-1-yl)-and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist σ2 activity. J Med Chem 2004; 47: 2308-17.
42. Kassiou M, Robert F, Dannals RF, et al. Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors, Bioorg Med Chem 2005; 13: 3623-26.
43. Tu Z, Dence CS, Ponde DE, et al. Carbon-11 labeled sigma-2 receptor ligands for imaging breast cancer. Nucl Med Biol 2005; 32: 423-30.
44. Abate C, Niso M, Lacivita E, Mosier PD, Toscano A, Perrone R. Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers. J Med Chem 2011; 54: 1022-32.
45. Berardi F, Abate C, Ferorelli S, et al. Exploring the importance of piperazine N-atoms for σ2 receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28). J Med Chem 2009; 52: 7817-28.
46. Abate C, Niso M, Contino M, et al. 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: mixed σ and human Δ8-Δ7 sterol isomerase ligands with antiproliferative and p-Glycoprotein inhibitory activity. Chem Med Chem 2011; 6: 73-80
47. Casellas P, Galiegue S, Bourrie B, Ferrini JB, Jbilo O, Vidal H. SR31747A: a peripheral σ ligand with potent antitumor activities. Anti-Cancer Drugs 2004; 15: 113-8.
48. Phase II Clinical Trial. ClinicalTrials.gov Identifier: NCT00174863. Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer (ODYSSEY).
49. Berardi F, Abate C, Ferorelli S, et al. Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Δ8-Δ7 Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity. J Med Chem 2008; 51: 7523-31.
50. Abate C, Mosier PD, Berardi F, Glennon RA. A structure-affinity and comparative molecular field analysis of sigma-2 (σ2) receptor ligands. Cent Nerv Syst Agents Med Chem 2009; 9: 246-57.
51. Glennon RA. Pharmacophore identification for sigma-1 (σ1) receptor binding: Application of the Deconstruction-Reconstruction-Elaboration approach. Mini Rev Med Chem 2005; 5: 927-40.
52. Cratteri P, Romanelli MN, Cruciani G, Bonacci C, Melani F. GRIND-derived pharmacophore model for a series of a-tropanyl derivative ligands of the sigma-2 receptor. J Comput Aided Mol Des 2004; 18: 361-74.
53. Glennon RA. Binding characteristics of σ2 receptor ligands. Braz J Pharm Sci 2005; 41: 1-12.
54. Laurini E, Zampieri D, Mamolo MG, et al. A 3D-pharmacophore model for σ2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. Bioorg Med Chem Lett 2010; 20: 2954-57.
55. Colabufo NA, Berardi F, Abate C, Contino M, Niso M, Perrone R. Is the σ2 receptor a histone binding protein? J Med Chem 2006; 49: 4153-8.
56. Abate C, Elenewski J, Niso M, et al. Interaction of the σ2 receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer. Chem Med Chem 2010; 5: 268-73.
57. Zeng C, Vangveravong S, Xu J, et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 2007; 67: 6708-16.
58. Zeng C, Vangveravong S, Jones LA, et al. Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Mol. Imaging 2011; 1-14.
59. Abate C, Hornick JR, Spitzer D, et al. Fluorescent Derivatives of σ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a Tool for Uptake and Cellular Localization Studies in Pancreatic Tumor Cells. J Med Chem 2011; 54: 5858-67.
60. Xu J, Zeng C, Chu W, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011; 2: 380.